Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fulvestrant

fulvestrant

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of fulvestrant

73 trials tracked of fulvestrant: 14 in phase 3 or 4 and 8 with published results. The most-cited published study has 714 citations.

73Trials tracked
14Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 2 Phase 3 12 Phase 2 48 Phase 1 10 Other / NA 1
  1. Phase 3 Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors Completed · 714 cited
  2. Phase 3 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Completed · 596 cited
  3. Phase 3 Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Completed · 539 cited
  4. Phase 3 S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Completed · 374 cited
  5. Phase 3 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women Completed · 133 cited
  6. Phase 3 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors Completed · 132 cited
Show 44 more trials
  1. Phase 3 Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Completed · 89 cited
  2. Phase 3 Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Completed · 34 cited
  3. Phase 4 A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed
  4. Phase 4 A Study of Abemaciclib in Indian Women With Advanced Breast Cancer Completed
  5. Phase 3 An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective Completed
  6. Phase 3 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Completed
  7. Phase 3 Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed
  8. Phase 3 Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy Completed
  9. Phase 2 A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg Completed
  10. Phase 2 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed
  11. Phase 2 AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. Completed
  12. Phase 2 Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Completed
  13. Phase 2 Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Completed
  14. Phase 2 Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy Completed
  15. Phase 2 Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer Completed
  16. Phase 2 Fulvestrant in Hormone Refractory Prostate Cancer Completed
  17. Phase 2 A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer Completed
  18. Phase 2 Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. Completed
  19. Phase 2 A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg Completed
  20. Phase 2 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis Completed
  21. Phase 2 Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Completed
  22. Phase 2 Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer Completed
  23. Phase 2 Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer Completed
  24. Phase 2 Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer Completed
  25. Phase 2 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments Completed
  26. Phase 2 Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients Completed
  27. Phase 2 A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Completed
  28. Phase 2 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed
  29. Phase 2 Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension Completed
  30. Phase 2 Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer Completed
  31. Phase 2 Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Completed
  32. Phase 2 Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer Completed
  33. Phase 2 A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Completed
  34. Phase 2 Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer Completed
  35. Phase 2 Faslodex in McCune-Albright Syndrome Completed
  36. Phase 2 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Completed
  37. Phase 2 A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Completed
  38. Phase 2 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer Completed
  39. Phase 2 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Completed
  40. Phase 2 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Completed
  41. Phase 2 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Completed
  42. Phase 2 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer Completed
  43. Phase 2 Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Completed
  44. Phase 2 Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 73 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Oncology RCT
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
May 22, 2026
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Drug Pipeline Cohort
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Frontiers Apr 24, 2026
FDA Approves Itovebi (Itovebi) for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Oncology FDA Approval
FDA Approves Itovebi (Itovebi) for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer FDA approves new breast cancer drug Itovebi for a specific type of advanced cancer
The FDA approved Itovebi in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, H…
A new oral drug, Itovebi, is now FDA-approved for advanced breast cancer with a specific genetic mutation, offering another option when horm…
FDA Apr 21, 2026
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
Oncology RCT
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…
Apr 20, 2026
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
Oncology Phase II
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Apr 17, 2026
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial
OB/GYN & Women's Health RCT
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial A New Pill Combo Helps Women with Advanced Breast Cancer Live Longer
A Phase III RCT of 874 endocrine-pretreated ER+/HER2- advanced breast cancer patients found imlunestrant monotherapy improved median OS vers…
A new pill combo helps women with advanced breast cancer live longer and delays the need for harsh chemotherapy.
Apr 12, 2026